Eventure Interactive (OTCBB: EVTI) $3.14. Today announced announced it has reached two mission critical data milestones to complement its social calendaring platform.With the successful creation and population of an Events Database comprised of over 20 Million Places and 8 Million Local Events listings, Eventure users will be able to access a valuable resource to quickly research possible venues and local events to assist them in identifying the right choice to make their daily events and activities even more relevant and meaningful.
Users can also access a "recommendations" feature that will suggest places and local events that potentially match a user's criteria based on Eventure's proprietary algorithm that socially ranks places and local events from the Events Database.
The Events Database will continue to grow organically as users create and add new places and new local events that are not found in the database.
"While Eventure continues to operate in invitation only mode, we are pleased to announce these milestones and as we continue to execute to our growth plan, and these serve as a solid foundation to our upcoming at-large release of the platform," says Gannon Giguiere, Eventure Interactive, Inc.'s Founder, CEO. "The Mission of Eventure from Day 1 has been to turn everyday events into meaningful memories by complementing our robust technology with meaningful data, whereby users will be able to turn to Eventure as their single source for planning events, experiencing them, and capturing and sharing the meaningful memories from those events."
What They Do: At Eventure, users will find a simple, yet elegant, web-to-mobile application where individuals can easily create, capture, and organize life's memories.
Prosensa Holding (Nasdaq: RNA), $6.76. Announced Monday after market close encouraging 48-week data from its U.S.-based, Phase II placebo-controlled study (DMD114876 or DEMAND V) of its lead compound, drisapersen, for the treatment of Duchenne Muscular Dystrophy (DMD).
The results of this study indicate that, compared to placebo, boys in the higher-dose drisapersen group (6 mg/kg once weekly) experienced stabilization and even improvements in their muscle function and physical activity as measured by the six-minute walk test (6MWT) for the 24-week treatment phase and maintained this improvement during the 24-week follow-up period. Additionally, when evaluating the percent-predicted six-minute walk distance (6MWD), a clinically meaningful treatment difference of 5.2% was observed at week 24 and 4.8% at week 48.
Principal investigator, Craig M. McDonald, M.D., Professor and Chair of Physical Medicine & Rehabilitation and Professor of Pediatrics at the University of California, Davis School of Medicine, will report the 48 week results in a poster session (Abstract #50) today at the Muscular Dystrophy Association 2014 Clinical Conference in Chicago, Illinois (March 16-19).
"Given the severity of the disease and the lack of disease modifying treatment options available, the results of this important study support the use of drisapersen at a dose of 6 mg/kg once weekly in the treatment of boys with DMD eligible for exon 51 skipping" Dr. McDonald said. "The maintenance of the clinically meaningful treatment benefit in the 24-week follow-up phase is very encouraging evidence for the drug's ability to produce prolonged stabilization of disease and may indicate that, at the 6 mg/kg once weekly dose, the drug has a long term treatment effect that helps delay disease progression in younger, less severe boys."
The study included 51 boys with DMD who were at least five years old, still able to walk and stand up from the floor without help in less than 15 seconds. As previously reported, boys in the group who received a 6mg/kg dose of drisapersen each week for the 24-week treatment period show a 27.1 meter improvement in the 6MWT (including a 16.1 m increase from baseline) over the boys in the placebo group at the end of the treatment period (p=0.069), indicating a clinically meaningful outcome for the primary endpoint. This study compared 6mg/kg/week with 3mg/kg/week and placebo and was not statistically powered to show a significant difference between the arms. A clinically meaningful treatment difference of 27.9 m over placebo (p=0.177) was maintained for 24 weeks after drisapersen administration ceased. This includes an overall mean increase from baseline of 14.7 m. In the drisapersen 6 mg/kg/week group, an improvement was seen in the percent-predicted 6MWD of 5.2% (p=0.051) and 4.8% (p=0.154) when compared to placebo at weeks 24 and 48, respectively.
Drisapersen at weekly doses of 3 and 6 mg/kg/week was generally well tolerated, although the majority of subjects treated with drisapersen reported injection-site reactions (none severe or serious). Renal abnormalities were common and occurred both in the placebo and drisapersen groups.
What They Do: Prosensa is an innovative biotechnology company engaged in the discovery and development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders.
Gulf Resources (Nasdaq: GURE) $2.75. Announced Monday after market close its financial results for the fourth quarter and fiscal year ended December 31, 2013.
Gulf Resources' revenue was $30.1 million for the fourth quarter of 2013, an increase of 36.5% from $22.0 million for the fourth quarter of 2012. The increase in net revenue was primarily attributable to the increased revenue from the entire three business segments include bromine segment, crude salt segment and chemical products segment.
For the fourth quarter of 2013, the Company incurred other income of $50,212, as compared to $13,302 for the corresponding quarter last year.
What They Do: Gulf Resources, Inc. operates through two wholly-owned subsidiaries, Shouguang City Haoyuan Chemical Company Limited and Shouguang Yuxin Chemical Industry Co., Limited.
Features available at SmallCapReview.com include in-depth profiles of select Small-Cap/Penny Stocks as well as the most comprehensive and up to date news available on the small-cap market.
No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. SmallCapReview has been compensated six thousand seven hundred fifty dollars by Eventure Interactive and expects to receive an additional six thousand seven hundred fifty dollars in the future for its efforts with regards to Eventure Interactive.
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play. To sign up visit SmallCapReview.com